Strategic Partnership Between Green Cross and Nanolek

The South Korean biopharmaceutical company Green Cross and the Russian pharmaceutical company Nanolek signed a strategic partnership agreement for the commercialisation of Green Cross’ biologics in the Russian market. 

Green Cross provides healthcare solutions that address the evolving needs of human health. The company is specialised in the development and manufacturing of plasma-derivatives, vaccines and recombinant proteins. The other one, Nanolek, is a fast-growing pharmaceutical company which aims to become one of the market leaders in the production of innovative biotechnological products and modern vaccines, stimulating the creation of the national bio-economy and amplifying the country’s biosafety. 

Under the terms of the agreement, Nanolek will obtain marketing authorisations and set up the production of a number of Green Cross’ biologics. The production will be organised at Nanolek’s facility, a state-of-art biopharmaceutical complex built and equipped in compliance with EU GMP standards and launched in December 2014. 

ADVERTISEMENT

“Our project with Green Cross will make socially significant drugs more accessible and minimize the state’s financial burden for the procurement of these drugs outside of Russia,” said Mikhail Nekrasov, CEO of Nanolek. “Making possible the domestic production of a number of biopharmaceuticals is our contribution to the implementation of the government policy in developing the Russian pharmaceutical industry.” 


Russia’s pharmaceutical market is one of the most attractive in the emerging European region, mainly due to its absolute size, a growing economy and increasing government investment in healthcare.

The Russian market is set to grow at twice the pace of the global pharmaceutical market, with growth estimates around 10-15% annually reaching an approximate market value of €43-60 billion by 2020. 

Previous post

OSE Pharma raised €21.1 Million

Next post

Scientists are racing to build a better diet soda

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.